



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige, et al.

Serial No.: 10/609,217

Group Art Unit No.: 1646

Filed: June 27, 2003

Examiner: S. Huff

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527B

REQUEST FOR CORRECTED FILING RECEIPT (PTO-103)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official Filing Receipt received from the PTO in the above application. Issuance of a corrected Filing Receipt is respectfully requested.

There is an error with respect to the following data, which is incorrectly entered and/or omitted.

Error In

Correct Data

Domestic Priority Data

This application is a ~~DIVCON~~ of 09/428,082 10/22/1999
which claims benefit of 60/105,371 10/23/1998.

Applicant therefore requests that the Filing Receipt be corrected.

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EV 352489049 US

Date of Deposit: October 31, 2003


I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lynne Buchsbaum
Printed Name

Lynne Buchsbaum
Signature

The Commissioner is hereby authorized to charge any fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Timothy J. Gaul". The signature is fluid and cursive, with the first name being the most prominent.

Timothy J. Gaul

Attorney/Agent for Applicants

Registration No.: 33,111

Phone: (805) 447-2688

Date: October 31, 2003

Please send all future correspondence to:
U.S. Patent Operations/ [TJG]
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/609,217	06/27/2003	1646	750	A-527B	37	11	1

CONFIRMATION NO. 5765

FILING RECEIPT



OC00000011034276

AMGEN INC.
U.S. Patent Operations/[TJG]
Dept. 4300, M/S 27-4-A
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Date Mailed: 10/15/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ulrich Feige, Newbury Park, CA;
Chuan-Fa Liu, Longmont, CO;
Janet C. Cheetham, Montecito, CA;
Thomas Charles Boone, Newbury Park, CA;

OCT 24 2003

Assignment For Published Patent Application

Amgen Inc.;

Domestic Priority data as claimed by applicant

This application is a CON of 09/428,082 10/22/1999
which claims benefit of 60/105,371 10/23/1998

Foreign Applications

If Required, Foreign Filing License Granted: 10/14/2003

Projected Publication Date: 01/22/2004

Non-Publication Request: No

Early Publication Request: No

Title

Modified peptides as therapeutic agents ✓

Preliminary Class

530

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).